Rigor Reviewed

Rigor-Reviewed Manuscript

Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies.

Name: Αlpha¹ Rigor Record — Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies.
Item: Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies.
Rating: 96
Author: Αlpha¹

Diebold M, Gauthier PT, Mayer KA, Mackova M, Hinze C, Chang J, Patel UD, Schütz E, Jilma B, Schrezenmeier E, Budde K, Böhmig GA, Halloran PF

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 5 high issues for “Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingBiological variables partially met−0.25★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.

Problems surfaced6 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Biological variables underreported (sex, age, strain)Assessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported molecular substudy of a randomized controlled trial, with strong ethics, data/code availability, and statistical methods. The main weaknesses are the lack of explicit randomization details and power analysis for the substudy, and the absence of age/sex-based analyses and main-text demographics.

Both reviewers classified the study as interventional, which is adopted. The evaluation covered all eight dimensions; several sub-criteria were marked not applicable (e.g., cell line authentication, housing conditions) due to the clinical nature of the study. The statistics verification component found no recomputable tests, so statistical correctness is not independently confirmed beyond the reported methods.

6 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior research on ABMR mechanisms, MMDx classification, and the prior felzartamab trial, acknowledging both the promise and limitations (e.g., recurrence after treatment). The rationale linking the need for molecular insights to the study objectives is explicit. Limitations of prior work are addressed by the design of this substudy, which provides comprehensive molecular characterization.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior work on ABMR pathogenesis, the MMDx system, and the prior clinical trial of felzartamab, and it articulates a logical rationale for the molecular analysis.

Evidence

paraphrase[Introduction, paragraph 1-3]

“Until recently, no therapy had been proven effective in suppressing ABMR activity or halting progression. However, a recent phase 2 trial of human IgG1 monoclonal anti-CD38 antibody felzartamab in kidney allograft recipients with active or chronic active ABMR has shown promise.”

paraphrase[Introduction, paragraph 4]

“Molecular analysis of ABMR biopsies can provide insights into the mode of action of interventions targeting CD38 in ABMR.”

paraphrase[Introduction, paragraph 4]

“While the previous study focused on clinical outcomes, the present study provides a comprehensive examination of the molecular features of the response...”

PASSReviewer 2· 90% conf

Evidence

paraphrase[Introduction, paragraph 1-3]

paraphrase[Introduction, paragraph 4]

“Molecular analysis of ABMR biopsies can provide insights into the mode of action of interventions targeting CD38 in ABMR.”

direct quote[Introduction, paragraph 3]

“However, in the biopsy 32 weeks after the last treatment, there was histological recurrence in three patients.”